Logo image of PLSE

PULSE BIOSCIENCES INC (PLSE) Stock Fundamental Analysis

USA - NASDAQ:PLSE - US74587B1017 - Common Stock

17.7 USD
-0.1 (-0.56%)
Last: 9/30/2025, 8:00:01 PM
17.72 USD
+0.02 (+0.11%)
After Hours: 9/30/2025, 8:00:01 PM
Fundamental Rating

2

PLSE gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 191 industry peers in the Health Care Equipment & Supplies industry. While PLSE has a great health rating, there are worries on its profitability. PLSE is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year PLSE has reported negative net income.
In the past year PLSE has reported a negative cash flow from operations.
In the past 5 years PLSE always reported negative net income.
PLSE had a negative operating cash flow in each of the past 5 years.
PLSE Yearly Net Income VS EBIT VS OCF VS FCFPLSE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M

1.2 Ratios

Looking at the Return On Assets, with a value of -56.57%, PLSE is doing worse than 67.54% of the companies in the same industry.
Looking at the Return On Equity, with a value of -65.11%, PLSE is in line with its industry, outperforming 46.07% of the companies in the same industry.
Industry RankSector Rank
ROA -56.57%
ROE -65.11%
ROIC N/A
ROA(3y)-62.31%
ROA(5y)-85%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
PLSE Yearly ROA, ROE, ROICPLSE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500 1K 1.5K 2K 2.5K

1.3 Margins

PLSE does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
PLSE Yearly Profit, Operating, Gross MarginsPLSE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -2K -4K -6K -8K

More info and screens

8

2. Health

2.1 Basic Checks

PLSE has more shares outstanding than it did 1 year ago.
PLSE has more shares outstanding than it did 5 years ago.
PLSE has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
PLSE Yearly Shares OutstandingPLSE Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
PLSE Yearly Total Debt VS Total AssetsPLSE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

2.2 Solvency

An Altman-Z score of 39.66 indicates that PLSE is not in any danger for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 39.66, PLSE belongs to the top of the industry, outperforming 98.43% of the companies in the same industry.
There is no outstanding debt for PLSE. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 39.66
ROIC/WACCN/A
WACCN/A
PLSE Yearly LT Debt VS Equity VS FCFPLSE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M

2.3 Liquidity

A Current Ratio of 12.05 indicates that PLSE has no problem at all paying its short term obligations.
PLSE has a Current ratio of 12.05. This is amongst the best in the industry. PLSE outperforms 96.34% of its industry peers.
A Quick Ratio of 12.04 indicates that PLSE has no problem at all paying its short term obligations.
PLSE has a Quick ratio of 12.04. This is amongst the best in the industry. PLSE outperforms 96.86% of its industry peers.
Industry RankSector Rank
Current Ratio 12.05
Quick Ratio 12.04
PLSE Yearly Current Assets VS Current LiabilitesPLSE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

More info and screens

0

3. Growth

3.1 Past

The earnings per share for PLSE have decreased strongly by -33.67% in the last year.
EPS 1Y (TTM)-33.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-43.09%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to decrease by -26.49% on average over the next years. This is quite bad
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-30%
EPS Next 2Y-26.49%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
PLSE Yearly Revenue VS EstimatesPLSE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2021 2022 2025 2026 2M 4M 6M 8M 10M
PLSE Yearly EPS VS EstimatesPLSE Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 -0.5 -1 -1.5 -2

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

PLSE reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year PLSE is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
PLSE Price Earnings VS Forward Price EarningsPLSE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
PLSE Per share dataPLSE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1

4.3 Compensation for Growth

PLSE's earnings are expected to decrease with -26.49% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-26.49%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

PLSE does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

PULSE BIOSCIENCES INC

NASDAQ:PLSE (9/30/2025, 8:00:01 PM)

After market: 17.72 +0.02 (+0.11%)

17.7

-0.1 (-0.56%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)08-12 2025-08-12/amc
Earnings (Next)10-28 2025-10-28
Inst Owners9.04%
Inst Owner Change5.05%
Ins Owners72.91%
Ins Owner Change0.32%
Market Cap1.19B
Analysts85.71
Price Target22.44 (26.78%)
Short Float %14.47%
Short Ratio13.7
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)450%
EPS NQ rev (1m)0%
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)N/A
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 11.4
P/tB 11.82
EV/EBITDA N/A
EPS(TTM)-0.7
EYN/A
EPS(NY)-1.47
Fwd EYN/A
FCF(TTM)-0.67
FCFYN/A
OCF(TTM)-0.66
OCFYN/A
SpS0
BVpS1.55
TBVpS1.5
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -56.57%
ROE -65.11%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-62.31%
ROA(5y)-85%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 22.78%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 12.05
Quick Ratio 12.04
Altman-Z 39.66
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)16.68%
Cap/Depr(5y)25.66%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-33.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-43.09%
EPS Next Y-30%
EPS Next 2Y-26.49%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-55.09%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-29.65%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-29.5%
OCF growth 3YN/A
OCF growth 5YN/A